PMV Pharmaceuticals (PMVP) Cash from Financing Activities (2019 - 2025)
PMV Pharmaceuticals' (PMVP) quarterly Cash from Financing Activities came in at $392000.0 in Q4 2025, up 127.91% YoY from $172000.0 in Q4 2024, and up 280.58% on a QoQ basis from $103000.0 in Q2 2025.
PMV Pharmaceuticals (PMVP) Cash from Financing Activities (2019 - 2025) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 7 years of Cash from Financing Activities data on file, last reported at $392000.0 in Q4 2025.
- Quarterly Cash from Financing Activities rose 127.91% year-over-year to $392000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $495000.0 (up 53.25% YoY) and the FY2025 annual result came in at $505000.0, up 61.34% from the prior year.
- Cash from Financing Activities improved to $392000.0 in Q4 2025, from $103000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $33.1 million in Q3 2023 to a low of $6000.0 in Q3 2022.
- A 5-year average of $2.3 million and a median of $276000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities tumbled 99.9% — and 2023, when it soared 552333.33%.
- Tracing PMVP's Cash from Financing Activities over 5 years: stood at $295000.0 in 2021, then jumped by 85.76% to $548000.0 in 2022, then tumbled by 47.45% to $288000.0 in 2023, then sank by 40.28% to $172000.0 in 2024, then soared by 127.91% to $392000.0 in 2025.
- The last three Cash from Financing Activities figures came in at $392000.0 (Q4 2025), $103000.0 (Q2 2025), and $10000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | PMV Pharmaceuticals | 70.74 Mn | -8.69 Mn | - | 143,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 392,000.00 |
| Dec 31, 2025 | 392,000.00 |
| Jun 30, 2025 | 103,000.00 |
| Jun 30, 2025 | 103,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 172,000.00 |
| Dec 31, 2024 | 172,000.00 |
| Jun 30, 2024 | 141,000.00 |
| Jun 30, 2024 | 141,000.00 |
| Dec 31, 2023 | 288,000.00 |
| Dec 31, 2023 | 288,000.00 |
| Sep 30, 2023 | 33.15 Mn |
| Sep 30, 2023 | 33.15 Mn |
| Jun 30, 2023 | 2.13 Mn |
| Jun 30, 2023 | 2.13 Mn |
| Mar 31, 2023 | 12,000.00 |
| Mar 31, 2023 | 12,000.00 |
| Dec 31, 2022 | 548,000.00 |
| Dec 31, 2022 | 548,000.00 |